Cargando…
Combining anti-IL-7Rα antibodies with autoantigen-specific immunotherapy enhances non-specific cytokine production but fails to prevent Type 1 Diabetes
Autoantigen-specific methods to prevent and treat Type 1 Diabetes (T1D) carry high hopes to permanently cure this disease, but have largely failed in clinical trials. One suggested approach to increase the efficacy of islet antigen-specific vaccination is to combine it with a modulator of the T cell...
Autores principales: | Vazquez-Mateo, Cristina, Collins, Justin, Goldberg, Sarah J., Lawson, Maxx, Hernandez-Escalante, Jaileene, Dooms, Hans |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433345/ https://www.ncbi.nlm.nih.gov/pubmed/30908554 http://dx.doi.org/10.1371/journal.pone.0214379 |
Ejemplares similares
-
Broad induction of immunoregulatory mechanisms after a short course of anti-IL-7Rα antibodies in NOD mice
por: Vazquez-Mateo, Cristina, et al.
Publicado: (2017) -
Emerging Therapeutic Strategies to Restore Regulatory T Cell Control of Islet Autoimmunity in Type 1 Diabetes
por: Volfson-Sedletsky, Victoria, et al.
Publicado: (2021) -
Autoantigen-Specific B-Cell Depletion Overcomes Failed Immune Tolerance in Type 1 Diabetes
por: Henry, Rachel A., et al.
Publicado: (2012) -
Identification of T-cell specific autoantigens
por: Hamann, D, et al.
Publicado: (2002) -
Preclinical Models to Evaluate the Human Response to Autoantigen and Antigen-Specific Immunotherapy in Human Type 1 Diabetes
por: Houeiss, Pamela, et al.
Publicado: (2022)